Department of Respiratory Medicine, School of Medicine, Kitasato University, Kanagawa, Japan.
Lung Cancer. 2013 Oct;82(1):143-8. doi: 10.1016/j.lungcan.2013.06.010. Epub 2013 Jul 31.
The leucine-rich repeat-containing G-protein-coupled receptor 5 (Lgr5), also known as Gpr49, has been identified as a marker of crypt basal columnar stem cells along the gastrointestinal tract and of bulge stem cells in the hair follicle. The aims of this study were to immunohistochemically examine Lgr5 expression in surgically resected non-small cell lung carcinomas (NSCLC), and evaluate the relationships between Lgr5 expression and the clinicopathological parameters and prognosis of patients.
Lgr5 expression was immunohistochemically studied in 266 consecutive resected NSCLCs, and its associations with clinicopathological parameters including TTF-1 and CDX-2 expressions were evaluated. Kaplan-Meier survival analysis and Cox proportional hazards models were used to estimate the effect of Lgr5 expression on survival.
Lgr5 was detected only in tumors with adenocarcinoma histology, and 16 cases were judged as positive. Among lung adenocarcinomas, Lgr5 expression was significantly associated with a larger tumor size (> 5 cm) (P = 0.033), higher pathological TNM stage of the disease (stage II and III) (P = 0.025), TTF-1-negative adenocarocinoma (P = 0.042), and poorer prognosis (P = 0.026). However, Lgr5 expression was not an independent predictor of poorer survival after controlling for clinicopathological factors.
The present study reveals that Lgr5 is expressed in a subset of lung adenocarcinoma, and its expression is related to some clinicopathological parameters and a poorer prognosis, although further studies are required to clarify the biological function of Lgr5 in lung adenocarcinoma.
富含亮氨酸重复序列的 G 蛋白偶联受体 5（Lgr5），也称为 Gpr49，已被鉴定为沿胃肠道的隐窝基底柱状干细胞和毛囊中的隆起干细胞的标志物。本研究的目的是免疫组织化学检查手术切除的非小细胞肺癌（NSCLC）中的 Lgr5 表达，并评估 Lgr5 表达与患者临床病理参数和预后之间的关系。
对 266 例连续切除的 NSCLC 进行了 Lgr5 表达的免疫组织化学研究，并评估了其与 TTF-1 和 CDX-2 表达等临床病理参数的相关性。Kaplan-Meier 生存分析和 Cox 比例风险模型用于估计 Lgr5 表达对生存的影响。
Lgr5 仅在具有腺癌组织学的肿瘤中检测到，其中 16 例被判断为阳性。在肺腺癌中，Lgr5 表达与更大的肿瘤大小（>5cm）（P=0.033）、更高的病理 TNM 分期（II 期和 III 期）（P=0.025）、TTF-1 阴性腺癌（P=0.042）和更差的预后（P=0.026）显著相关。然而，在控制临床病理因素后，Lgr5 表达并不是较差生存的独立预测因子。
本研究表明，Lgr5 在肺腺癌的一个亚群中表达，其表达与一些临床病理参数和较差的预后相关，尽管需要进一步研究来阐明 Lgr5 在肺腺癌中的生物学功能。
